Skip to ContentSkip to Navigation
Over ons Praktische zaken Waar vindt u ons dr. W.W.H. Roeloffzen

Publicaties

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018

Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study

Increased mortality risk in multiple-myeloma patients with subsequent malignancies: a population-based study in the Netherlands

LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

Conditioning With High Dose Total Body Irradiation And Post Transplantation Cyclophosphamide in Early Relapsed Multiple Myeloma Patients Receiving Allogeneic Stem Cell Transplantation

Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis

Neurofilament light chain, a biomarker for polyneuropathy in systemic amyloidosis

A real-life cohort study of immunoglobulin light-chain (AL) amyloidosis patients ineligible for autologous stem cell transplantation due to severe cardiac involvement or advanced disease

Lees meer